Abeona Therapeutics

Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.

Find a broker to begin trading ABEO now

Company Name Abeona Therapeutics
Market/Symbol NASDAQ: ABEO
Recent Price
Market Cap $239.52M
Avg. Daily Vol. (3m) 251,734
Price/Book N/A
Price/Cash Flow 30x
As of May. 23, 2017
*Source: QuoteMedia

Begin trading ABEO

 Find Broker

Recent Company Videos

Abeona Therapeutics: Developing & Delivering Rare Gene Therapies

Dec. 2, 2015

Dave Gentry, host of "The RedChip Money Report", interviews Timothy Miller, PhD, President & CEO of Abeona Therapeutics (NASDAQ: ABEO). Abeona ...

Abeona Therapeutics Latest News

Ask the CEO

Want more information? View our latest virtual conference.

Receive ABEO Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market